ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

Rhea-AI Summary

ViaDerma Inc (VDRM), a specialty pharmaceutical company, has issued a statement confirming its continued operations amid concerns. The company acknowledged it has overdue annual and quarterly financial reports and is actively working to complete them. Management emphasized that the company is not defunct and continues to pursue its business objectives while exploring strategic options for future growth. The brief announcement appears aimed at addressing investor concerns about the company's operational status and regulatory compliance efforts.

Positive

• None.

Negative

• Company has failed to file required annual and quarterly financial reports
• Trading restricted to OTC Expert Market, indicating compliance issues
• Lack of specific timeline for completing overdue financial reports

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial reports.

The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC Expert Market: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com.

Any forecast of future performance is a "forward-looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111

FAQ

Is ViaDerma (VDRM) still in business in 2025?

Yes, ViaDerma confirmed it remains fully operational and is not defunct, though it is working to complete overdue financial reports.

Why is VDRM stock trading on the OTC Expert Market?

VDRM trades on the OTC Expert Market likely due to compliance issues, including overdue annual and quarterly financial reports.

What financial reports are missing for ViaDerma (VDRM)?

The company has overdue annual and quarterly financial reports, though specific periods were not disclosed in the announcement.

What strategic options is ViaDerma (VDRM) exploring?

While the company stated it is exploring strategic options, no specific details were provided about the nature of these options.